Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit

References

• Silverman LB, Gelber RD, Dalton VK, et al Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91–01. Blood 2001;97:1211–1218.
   PubMed Web of Science ®Google Scholar
• Pui CH, Sandlund JT, Pei D, et al Total Therapy Study XIIIB at St Jude Children's Research Hospital. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004;104:2690–2696.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia–current status and future perspectives. Lancet Oncol 2001;2:597–607.
   PubMed Web of Science ®Google Scholar
• Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;85:1416–1434.
   PubMed Web of Science ®Google Scholar
• Szczepański T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia 2007;21:622–626.
   PubMed Web of Science ®Google Scholar
• Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 2005;90:382–390.
   PubMed Web of Science ®Google Scholar
• Szczepański T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukemia. Best Pract Res Clin Haematol 2002;15:37–57.
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2000;14:783–785.
   PubMed Web of Science ®Google Scholar
• Béné MC, Kaeda JS. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European Leukemia Net. Hematologica 2009;94:1135–1150.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, et al The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlations. Br J Haematol 1981;47:553–561.
   PubMed Web of Science ®Google Scholar
• Tzortzatou-Stathopoulou F, Moschovi MA, Papadopoulou AL, et al Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors? Eur J Haematol 2005;75:361–369.
   PubMed Web of Science ®Google Scholar
• Pongers-Willemse MJ, Seriu T, Stolz F, et al Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia? Leukemia 1999;13:110–118.
   PubMed Web of Science ®Google Scholar
• Meleshko AN, Lipay NV, Stasevich IV, Potapnev MP. Rearrangements of IgH, TCRD and TCRG genes as clonality marker of childhood acute lymphoblastic leukemia. Exp Oncol 2005;27:319–324.
   PubMed Web of Science ®Google Scholar
• Yokota S, Hansen-Hagge TE, Ludwig WD, et al Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991;77:331–339.
   PubMed Web of Science ®Google Scholar
• Botsonis T, Tsangaris GT, Mikraki V, Tzortzatou-Stathopoulou F. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes. Anticancer Res 1999;19:2211–2220.
   PubMed Web of Science ®Google Scholar
• Braoudaki M, Karpusas M, Katsibardi K, Papathanassiou C, Karamolegou K, Tzortzatou-Stathopoulou F. Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. Med Oncol 2008 Dec 16. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• van der Velden VH, Szczepanski T, Wijkhuijs JM, et al Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia 2003;17:1834–1844.
   PubMed Web of Science ®Google Scholar
• Dawidowska M, Derwich K, Szczepański T, et al Pattern of immunoglobulin and T-cell receptor (Ig/TCR) gene rearrangements in Polish pediatric acute lymphoblastic leukemia patients–implications for RQ-PCR-based assessment of minimal residual disease. Leuk Res 2006;30:1119–1125.
   PubMed Web of Science ®Google Scholar
• Cole-Sinclair M, Foroni L, Wright F, Mehta A, Prentice HG, Hoffbrand AV. Minimal residual disease in acute lymphoblastic leukemia–PCR analysis of immunoglobulin gene rearrangements. Leuk Lymphoma 1993;11:49–58.
   PubMed Web of Science ®Google Scholar
• Steenbergen EJ, Verhagen OJ, van Leeuwen EF, von dem Borne AE, van der Schoot CE. Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. Blood 1993;82:581–589.
   PubMed Web of Science ®Google Scholar
• van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ. Detection of minimal residual disease in acute leukemia. J Biol Regul Homeost Agents 2004;18:146–154.
   PubMed Web of Science ®Google Scholar
• Zhou J, Goldwasser MA, Li A, et al Dana-Farber Cancer Institute ALL Consortium. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95–01. Blood 2007;110:1607–1611.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Sancho J, Hancock ML, et al Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691–2696.
   PubMed Web of Science ®Google Scholar
• Scrideli CA, Queiroz RG, Bernardes JE, Valera ET, Tone LG. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification. Med Pediatr Oncol 2003;41:10–16.
   PubMedGoogle Scholar
• Mortuza FY, Papaioannou M, Moreira IM, et al Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002;20:1094–1104.
   PubMed Web of Science ®Google Scholar
• Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997;336:317–323.
   PubMed Web of Science ®Google Scholar
• Marshall GM, Haber M, Kwan E, et al Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:704–709.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 1998;352:1731–1738.
   PubMed Web of Science ®Google Scholar
• Martínez-Ramírez A, Urioste M, Contra T, et al Fluorescence in situ hybridization study of TEL/AML1 fusion and other abnormalities involving TEL and AML1 genes. Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia. Haematologica 2001;86:1245–1253.
   PubMed Web of Science ®Google Scholar
• Borkhardt A, Cazzaniga G, Viehmann S, et al Incidence and clinical relevance of TEL/AML1 fusion gene in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. Blood 1997;90:571–577.
   PubMed Web of Science ®Google Scholar
• Liang DC, Chou TB, Chen JS, et al High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996;10:991–993.
   PubMed Web of Science ®Google Scholar
• Park KU, She CJ, Shin HY, et al Low incidence of TEL/AML1 fusion and TEL deletion in Korean childhood acute leukemia by extra-signal fluorescence in situ hybridization. Cancer Genet Cytogenet 2001;126:73–77.
   PubMed Web of Science ®Google Scholar
• Loh ML, Goldwasser MA, Silverman LB, et al Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95–01. Blood 2006;107:4508–4513.
   PubMed Web of Science ®Google Scholar
• Woo HY, Kim DW, Park H, Seong KW, Koo HH, Kim SH. Molecular cytogenetic analysis of gene rearrangements in childhood acute lymphoblastic leukemia. J Korean Med Sci 2005;20:36–41.
   PubMed Web of Science ®Google Scholar
• Harbott J, Viehmann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997;90:4933–4937.
   PubMed Web of Science ®Google Scholar